Expert knowledge for digital decisions
How to Plan Post-Market Surveillance for Software?
Short answer
Introduction to Post-Market Surveillance
Post-Market Surveillance (PMS) is an essential part of the lifecycle of software classified as a medical device. It serves to continuously monitor the safety and effectiveness of the product after its market launch. This is particularly important as software products often undergo updates and changes that can potentially impact their performance.
Planning the PMS
Planning the PMS should begin during the software development phase. It is important to define clear objectives that will guide the monitoring. This includes establishing methods for data collection that can encompass both qualitative and quantitative data. User feedback plays a crucial role as it provides valuable information about the user experience and potential issues.
Data Collection and Analysis
Data collection can be carried out through various methods, such as surveys, interviews, or the analysis of support requests. Additionally, incidents that occur during the use of the software should be systematically recorded and analyzed. The collected data must be regularly evaluated to identify trends and potential risks early.
Documentation and Compliance
Documenting all steps in the PMS process is critical. It ensures traceability and helps demonstrate compliance with legal requirements. The documentation should also include the results of data analyses as well as the measures taken to mitigate risks.
Conclusion
A well-planned and executed post-market surveillance is essential to ensure the safety and effectiveness of software products in healthcare. By systematically collecting and analyzing data, potential issues can be identified and addressed early, ultimately contributing to higher patient safety.
Key facts
- Objective of PMS
- Ensure the safety and performance of the software
- Methods for Data Collection
- User feedback and incident monitoring
- Regular Evaluations
- Identification of potential risks
Sources
All external claims are backed by traceable sources.-
01
Verordnung (EU) 2017/745 über Medizinprodukte EUR-Lex / Europäische Union
-
02
MDCG-Leitlinien für Medizinprodukte und Medical Device Software Europäische Kommission